Access to information about drugs is essential for the quality use of medicines. Pharmaceutical companies and regulatory agencies, such as the Therapeutic Goods Administration (TGA), hold large quantities of information about individual drugs, but do not always share this information. To encourage transparency,Australian Prescriberrates companies' willingness to provide clinical information about new drugs.Table 1shows how the companies have performed between January 2009 and December 2010.

The TGA is now publishing Australian Public Assessment Reports (AusPARs) for prescription medicines. While the Editorial Executive Committee welcomes this move to greater transparency, it will still ask companies to provide the clinical evaluations for their new products. While there are similarities, the AusPAR may not include all the details found in the regulator's clinical evaluation.

For 2011, the T-score has been revised to include the AusPAR.

The revised T-scores will be as follows:

Read about The Transparency Score

manufacturer provided complete clinical evaluation

Read about The Transparency Score

manufacturer provided additional useful information

manufacturer provided the AusPAR and/or the product information

manufacturer declined to supply data
manufacturer did not respond to request for data

Table 1
Pharmaceutical company responses to requests for clinical evaluation data for drugs marketed Jan 2009 – Dec 2010
Company Drug
Read about The Transparency Score manufacturer provided clinical evaluation
Amgen denosumab
Ferring degarelix
Pfizer anidulafungin
PharmaLink cilostazol
Phebra caffeine citrate
Roche methoxy polyethylene glycol-epoetin beta
Sanofi Pasteur H5N1 influenza vaccine
Shire icatibant
Wyeth methylnaltrexone
Read about The Transparency Score manufacturer provided additional useful information
Abbott omega-3-acid ethyl esters
Celgene azacitidine
Commercial Eyes melatonin
CSL H1N1 influenza vaccine
Japanese encephalitis vaccine
Eli Lilly prasugrel
Company Drug
Genzyme plerixafor
GlaxoSmithKline pneumococcal polysaccharide conjugate vaccine
Merck Sharp & Dohme rizatriptan
Orphan nitisinone
Sanofi-Aventis alfuzosin
Servier agomelatine
UCB Pharma certolizumab pegol
Wyeth desvenlafaxine succinate
manufacturer provided only the product information
Actelion miglustat
Baxter Healthcare vaccinia smallpox vaccine
Bayer Schering rivaroxaban
CSL nebivolol
GlaxoSmithKline dutasteride
Hospira clofarabine
Janssen-Cilag doripenem
Merck Sharp & Dohme etoricoxib
Novartis valsartan, amlodipine/valsartan, valsartan/hydrochlorothiazide
Phebra arsenic trioxide
Sanofi Pasteur influenza seasonal vaccine
UCB Pharma lacosamide
manufacturer declined to supply data
Boehringer Ingelheim dabigatran etexilate
CSL H5N1 influenza vaccine
CSL Bioplasma human C1 esterase inhibitor
Ipsen triptorelin embonate
Janssen-Cilag etravirine
Merck Sharp & Dohme golimumab
Novartis indacaterol
manufacturer did not respond to request for data
Alexion Pharmaceuticals eculizumab
GlaxoSmithKline ambrisentan
H5N1 influenza vaccine